PerkinElmer expands epigenetic detection reagents portfolio

PerkinElmer has announced the expansion of its epigenetic detection reagents portfolio as it responds to trends in drug development.

The science company's range of epigenetic and post-translational screening tools has been broadened to encompass nine different histone marks and more than 15 validated enzyme assays, aiding in the discovery of new drugs targeting epigenetic enzymes.

These assays are built upon the firm's proprietary LANCEUltra and AlphaLISA technology, offering specificity, sensitivity, dynamic range and high throughput levels.

Dr Martina Bielefeld-Sevigny, vice-president and general manager for drug discovery and research reagent solutions for PerkinElmer's bio-discovery unit, said the new products are being launched due to the rising importance of research into epigenetic drug targets.

"PerkinElmer is committed to providing rapid advances for both academia and the pharmaceutical industry, offering robust enabling tools to work with these important targets," she added.

This week, the company also announced the launch of a new oncology testing service, which incorporates its OncoChip microarray technology for optimum performance.